SX-682 is a potent and selective CXCR1/2 allosteric inhibitor, it may be useful for castration-resistant prostate cancer. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity. CXCR1 and CXCR2 chemokine receptors and their ligands (CXCL1/2/3/7/8) play an important role in tumor progression.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 120 mg/mL|
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Lillian Sun, et al. JCI Insight. 2019 Apr 4;4(7):e126853. PMID: 30944253.
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu, et al. Nature. 2017 Mar 30;543(7647):728-732. PMID: 28321130.
|Related CXCR Products|
LY2510924 is a potent and selective CXCR4 antagonist, which blocks SDF-1 binding to CXCR4 with IC50 of 0.079 nM.
Motixafortide (BL-8040) is an antagonist of CXCR4 with IC50 value of 1 nM.
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4).
VUF11207 fumarate is a CXCR7 agonist and a high-potency CXCR7 ligand (pKi=8.1).
JMS-17-2 is a potent and selective CX3CR1 antagonist with IC50 of 0.32 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.